share_log

Ladenburg Thalmann Maintains Buy on United Therapeutics, Lowers Price Target to $256

Benzinga ·  May 4, 2023 07:45

Ladenburg Thalmann analyst Matthew Kaplan maintains United Therapeutics (NASDAQ:UTHR) with a Buy and lowers the price target from $285 to $256.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment